Medicine overview
Indications of Viscotin
Established / FDA-Approved Uses
- Mucolytic therapy: Viscotin is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in acute and chronic bronchopulmonary diseases, including chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis, and pneumonia, as well as in atelectasis due to mucus obstruction, pulmonary complications following thoracic or cardiovascular surgery, tracheostomy care, and during anesthesia.
- Antidote for acetaminophen (paracetamol) overdose: Viscotin (oral and intravenous formulations) is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen, based on a plasma level plotted on the Rumack-Matthew nomogram or a history of significant ingestion.
Adjunct / Diagnostic Uses
- Used as an adjunct in diagnostic bronchial studies (e.g., bronchograms) to help clear mucus obstructing the field of view.
Viscotin mucolytic use requires appropriate airway clearance technique and, where applicable, concomitant bronchodilator therapy; treatment decisions should always be individualized by a physician.
Composition
Acetylcysteine is available in multiple formulations depending on manufacturer and market, including oral effervescent tablets/granules, oral solution, inhalation (nebulizer) solution, and sterile intravenous injection. Strength and formulation vary by product (for example, 10% and 20% inhalation solutions, oral strengths such as 200 mg and 600 mg, and 200 mg/mL injection) - confirm exact composition on the specific product label.
Description
Viscotin is the N-acetyl derivative of the amino acid L-cysteine and functions both as a mucolytic agent and as a specific antidote. As a mucolytic, its free sulfhydryl group opens disulfide bonds in mucoprotein complexes, reducing the viscosity of respiratory secretions and facilitating their clearance. As an antidote, Viscotin is used in acetaminophen (paracetamol) overdose, where it restores hepatic glutathione stores and provides an alternate route for detoxifying the reactive, hepatotoxic acetaminophen metabolite. Viscotin is administered orally, by nebulization/direct instillation, or intravenously depending on the clinical indication.
Therapeutic Class
Mucolytic agent; Antidote (specific antidote for acetaminophen/paracetamol hepatotoxicity)
Pharmacology
Acetylcysteine's mucolytic action is attributed to its free sulfhydryl (thiol) group, which opens the disulfide bonds that cross-link glycoprotein strands in mucus, lowering mucus viscosity and facilitating expectoration; this action is more pronounced at pH 7-9.
In acetaminophen (paracetamol) overdose, Acetylcysteine acts as a precursor of glutathione, restoring hepatic glutathione stores that are depleted by the toxic acetaminophen metabolite N-acetyl-p-benzoquinone imine (NAPQI). Acetylcysteine may also act as an alternate substrate for conjugation with NAPQI, thereby preventing or limiting hepatocellular injury when given promptly.
Dosage & Administration of Viscotin
Mucolytic Use (Nebulization / Direct Instillation)
| Route | Adult Dose | Frequency |
|---|---|---|
| Nebulization | 3-5 mL of 20% solution or 6-10 mL of 10% solution | 3-4 times daily |
| Direct instillation (e.g., tracheostomy) | 1-2 mL of 10-20% solution | Every 1-4 hours as needed |
Dose and frequency should be individualized by the treating physician based on the severity of the condition and clinical response.
Antidote for Acetaminophen (Paracetamol) Overdose
| Route | Regimen |
|---|---|
| Oral (72-hour protocol) | Loading dose 140 mg/kg, then 70 mg/kg every 4 hours for 17 additional doses |
| Intravenous (21-hour protocol) | 150 mg/kg over 60 minutes, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours, diluted in a compatible IV fluid per product labeling and local hospital protocol |
Treatment for acetaminophen overdose is time-critical and should be initiated as soon as possible, ideally within 8-10 hours of ingestion, based on a serum acetaminophen level plotted on the Rumack-Matthew nomogram (when time of ingestion is known) or based on history/clinical suspicion of a potentially toxic ingestion. This must only be undertaken under direct medical supervision, typically in an emergency or poison-control setting.
No well-established dose adjustment for renal or hepatic impairment exists for the mucolytic indication; for the antidote indication, Viscotin is used specifically because of hepatotoxicity risk, and dosing follows the standard weight-based protocol with close monitoring of hepatic function.
Administration of Viscotin
Viscotin inhalation solution is administered via nebulizer using a face mask, mouthpiece, or tracheostomy attachment, or by direct instillation into the airway; a bronchodilator should be available for inhaled use, particularly in patients with asthma or reactive airway disease. Effervescent tablets/granules for oral use should be fully dissolved in water and consumed promptly. Intravenous Viscotin must be diluted in a compatible intravenous fluid and administered as an infusion strictly per the prescribed protocol, under medical supervision.
Interaction of Viscotin
Activated Charcoal
When activated charcoal is co-administered for gastrointestinal decontamination after acetaminophen overdose, it may adsorb orally administered Viscotin and theoretically reduce its absorption; this is generally not considered clinically significant at standard antidote dosing, but administration timing may be adjusted by the treating physician. Intravenous Viscotin avoids this interaction entirely.
Nitroglycerin
Concomitant use with nitroglycerin and other nitrates may potentiate the vasodilatory and hypotensive effects of nitrates; this is a recognized but uncommon interaction that may warrant clinical monitoring.
Viscotin inhalation solution should not be mixed in the same nebulizer with other drugs unless compatibility has been established, as this may cause chemical inactivation.
Contraindications
Acetylcysteine is contraindicated in patients with known hypersensitivity to Acetylcysteine or any component of the formulation.
Side Effects of Viscotin
Common
- Nausea and vomiting (particularly with oral antidote use, related to the unpleasant taste and sulfurous odor)
- Rhinorrhea, drowsiness, and stomatitis (with inhaled use)
Less Common / Serious
- Bronchospasm/bronchoconstriction, especially in patients with asthma or hyperreactive airways receiving inhaled/nebulized Viscotin
- Rash, urticaria, flushing, pruritus, and anaphylactoid (non-IgE-mediated) reactions, notably with intravenous antidote use; these are usually mild-to-moderate, dose- and rate-related, and typically managed by slowing or briefly pausing the infusion rather than representing true drug allergy
- Fever, chills, and hypotension (rare, with IV use)
Pregnancy & Lactation
For the mucolytic indication, Viscotin should be used during pregnancy or breastfeeding only if clearly needed, after potential benefit has been weighed against potential risk to the fetus or infant; a physician should be consulted before use.
For treatment of acetaminophen overdose during pregnancy, Viscotin is generally recommended because untreated acetaminophen toxicity poses a serious risk of maternal hepatic failure and fetal harm; in this life-threatening context, the benefit of prompt antidote treatment is considered to clearly outweigh potential risk, but treatment should always be directed by a physician.
Limited data are available on excretion of Viscotin into breast milk; a physician should be consulted regarding breastfeeding during treatment.
Precautions & Warnings
Time-critical antidote use: When used for acetaminophen (paracetamol) overdose, Viscotin must be given as early as possible per an established nomogram-based protocol, and only under direct medical supervision in a hospital or emergency setting; delayed treatment reduces effectiveness in preventing hepatotoxicity.
Bronchospasm risk with inhaled use: Viscotin given by nebulization or direct instillation can provoke bronchospasm, particularly in patients with asthma or reactive airway disease. A bronchodilator should be available and administered if bronchospasm occurs, and inhaled therapy should be discontinued if significant bronchospasm develops.
Anaphylactoid reactions with IV use: Rash, flushing, and anaphylactoid reactions can occur with intravenous Viscotin even though they are not true IgE-mediated allergic reactions; patients should be monitored during infusion, and the infusion rate slowed or paused if reactions occur.
Hepatic monitoring: In acetaminophen overdose, liver function, coagulation status, and renal function should be monitored throughout treatment as directed by the treating physician.
Overdose Effects of Viscotin
Specific data on overdose of Viscotin itself are limited, as it is generally well tolerated even at the high doses used as an antidote; excessive or too-rapid administration, especially intravenously, may increase the risk of nausea, vomiting, flushing, or anaphylactoid-type reactions. If an excessive dose is suspected, or if features of a hypersensitivity/anaphylactoid reaction occur, seek immediate medical attention or contact a poison control center/emergency services; treatment is supportive and should be managed by a physician. Note that Viscotin is itself used to treat acetaminophen overdose, which is a separate medical emergency requiring urgent care regardless of Viscotin dosing.
Storage Conditions
Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Once opened, oral solution/effervescent preparations should be used within the timeframe stated on the product label, and intravenous vials are for single use only - discard any unused portion.
Use In Special Populations
Renal impairment: No well-established dose adjustment is required for the mucolytic indication; in acetaminophen overdose, the standard weight-based antidote protocol is used with clinical monitoring.
Hepatic impairment: Viscotin is itself used to prevent/limit acetaminophen-induced hepatic injury; in patients with pre-existing liver disease receiving Viscotin for overdose, liver function should be closely monitored by the treating physician.
Elderly: No specific dose adjustment is established for elderly patients; use with the same clinical monitoring as adults.
Pediatric patients: See Pediatric Uses.
Duration Of Treatment
For mucolytic use, duration is individualized by the treating physician based on the underlying respiratory condition and response, ranging from short-term (e.g., peri-operative or acute illness) to longer-term use in chronic conditions such as cystic fibrosis or chronic bronchitis. For acetaminophen overdose, Viscotin is given as a fixed-course antidote protocol (commonly 21 hours intravenously or 72 hours orally), which may be extended if there is evidence of ongoing hepatotoxicity or a high-risk ingestion, per physician/protocol assessment.
Reconstitution
Effervescent Viscotin tablets or granules should be fully dissolved in the recommended volume of water immediately before oral administration. Viscotin inhalation solution may be diluted with normal saline or sterile water for injection if a lower concentration is desired for nebulization. Intravenous Viscotin must be diluted in a compatible intravenous fluid (e.g., dextrose 5% in water) according to product labeling before infusion; it should not be administered undiluted.
Drug Classes
Mucolytics; Antidotes (specifically, the antidote for acetaminophen/paracetamol poisoning)
Mode Of Action
Acetylcysteine's free thiol (-SH) group cleaves disulfide bonds within mucoprotein complexes, reducing mucus viscosity for the mucolytic effect. In acetaminophen toxicity, Acetylcysteine restores hepatic glutathione stores and provides an alternate route for detoxifying the reactive metabolite NAPQI, protecting the liver from acetaminophen-induced injury when administered promptly.
Pregnancy
B
Pediatric Uses
Viscotin for acetaminophen overdose is used in pediatric patients of all ages using the same weight-based oral or intravenous protocol as adults, with dosing calculated according to the child's body weight; treatment should always be supervised by a physician or poison control center given the narrow, time-critical treatment window.
For the mucolytic indication, Viscotin may be used in pediatric patients under medical supervision with dose individualized by age/weight and clinical condition; safety and efficacy for all pediatric mucolytic uses have not been as extensively established as for the antidote indication, so use should be guided by a pediatrician.
Frequently Asked Questions
Q: What is Viscotin 3 ml Nebuliser Solution used for?
A: Viscotin 3 ml Nebuliser Solution is used as a mucolytic to thin thick mucus in certain lung conditions, and as the specific antidote for acetaminophen (paracetamol) overdose to help prevent liver damage.
Q: How quickly must Viscotin 3 ml Nebuliser Solution be given after an acetaminophen overdose?
A: Viscotin 3 ml Nebuliser Solution is most effective when started as early as possible, ideally within 8-10 hours of acetaminophen ingestion, based on a doctor's assessment using blood levels and a standard nomogram; treatment should never be delayed while awaiting test results if a significant overdose is suspected.
Q: Can Viscotin 3 ml Nebuliser Solution cause an allergic-type reaction?
A: Yes. Intravenous Viscotin 3 ml Nebuliser Solution can cause flushing, rash, or anaphylactoid reactions that resemble an allergic reaction, even though they are usually not a true drug allergy. These reactions are generally managed by slowing the infusion; tell your medical team immediately if you notice a rash, flushing, or difficulty breathing.
Q: Is Viscotin 3 ml Nebuliser Solution safe during pregnancy?
A: For routine mucolytic use, Viscotin 3 ml Nebuliser Solution should only be used during pregnancy if clearly needed, after discussing potential risks and benefits with a physician. If used as the antidote for acetaminophen overdose during pregnancy, the benefit of preventing severe liver damage is considered to outweigh the risk, since untreated overdose is a serious threat to both mother and baby.
Q: Can inhaled Viscotin 3 ml Nebuliser Solution cause breathing problems?
A: Inhaled/nebulized Viscotin 3 ml Nebuliser Solution can occasionally trigger bronchospasm (tightening of the airways), especially in people with asthma. A bronchodilator is usually kept available during treatment, and your doctor may stop the inhaled therapy if breathing difficulty occurs.
Q: What should I do if I think someone has taken too much Viscotin 3 ml Nebuliser Solution?
A: Seek immediate medical attention or contact a poison control center or emergency services. Overdose of Viscotin 3 ml Nebuliser Solution itself is uncommon since it is generally well tolerated, but any suspected overdose situation - especially in the context of acetaminophen poisoning - needs urgent medical evaluation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.
